Barriers to Adherence to Iron Chelation Therapy in Thalassemia Patients

Authors

  • Tanuka Barua Department of Paediatrics, Chattogram Maa-O-Shishu Hospital Medical College, Chattogram, Bangladesh
  • Golam Mohammed Tayab Ali Department of Paediatrics, Rangamati Medical College, Rangamati, Bangladesh
  • Rana Chowdhury Department of Paediatrics, Chattogram Maa-O-Shishu Hospital Medical College, Chattogram, Bangladesh
  • Dhananjoy Das Department of Paediatrics, Chattogram Maa-O-Shishu Hospital Medical College, Chattogram, Bangladesh
  • Showrov Barua Chowdhury Department of Paediatrics, Chattogram Maa-O-Shishu Hospital Medical College, Chattogram, Bangladesh
  • Mahmud Ahmed Chowdhury Arzu Department of Paediatrics, Chattogram Maa-O-Shishu Hospital Medical College, Chattogram, Bangladesh

DOI:

https://doi.org/10.3329/cmoshmcj.v20i2.56473

Keywords:

Iron chelating drugs; Non-adherence; Thalassemia

Abstract

Background: Thalassemias are the most common inheritable blood disorders requiring regular blood transfusions and iron chelating therapy. Non-adherence to iron chelation therapy increases complications and is a problem in treating thalassemia. To assess the reasons of non-adherence to iron chelating drug in treating thalassemia.

Materials and methods: This descriptive cross-sectional study was carried out in the thalassemia ward of Chattogram Maa Shishu-O-General Hospital, Chattogram from July, 2013 to June, 2014. 70 thalassemia patients aged 2-18 years previously treated with iron chelating drugs were included. Parents were interviewed according to a formulated questionnaire based on discontinuation of iron chelating drugs and its reasons. Data were analyzed by both manually and by SPSS-18.

Results: About 48.6% patients needed blood transfusion >10 units/year and 62.9% patients were prescribed with iron chelating drugs. Near about half patients (47.7%) did not continued iron chelating therapy till full prescribed period. Deferiprone (31.8%) and combination of deferipronc & desferrioxamine (31.8%) was the most commonly prescribed drug. Deferiprone is the drug to which most of the patients (70%) were adherent and a good number of patients (65%) discontinued desferrioxamine. Financial problem (100%) was the only reason for discontinuation of oral chelator. In case of parenteral chelator, besides finanacial problem (38.5%), time consuming natures (38.5%), need of hospital admission (23%) are the other causes for non-adherence to iron chelation therapy.

Conclusion: Financial problem is the main cause of non-adherence to iron chelation therapy. Iron chelating drugs should be available at low cost.

Chatt Maa Shi Hosp Med Coll J; Vol.20 (2); July 2021; Page 45-49

Downloads

Download data is not yet available.
Abstract
51
PDF
42

Downloads

Published

2021-11-11

How to Cite

Barua, T. ., Tayab Ali, G. M. ., Chowdhury, R. ., Das, D. ., Chowdhury, S. B. ., & Chowdhury Arzu, M. A. . (2021). Barriers to Adherence to Iron Chelation Therapy in Thalassemia Patients. Chattagram Maa-O-Shishu Hospital Medical College Journal, 20(2), 45–49. https://doi.org/10.3329/cmoshmcj.v20i2.56473

Issue

Section

Original Articles